Through research at JSR · Keio University Medical Chemistry Innovation Center (JKiC), JSR will promote the development of technologies and diagnostic agents related to maintaining homeostasis of intestinal flora. One example is to fight Klebsiella bacteria which may colonize the oral cavity and the digestive tract if homeostasis is disturbed, leading to inflammatory bowel disease. JSR has granted an exclusive license of key intellectual property involved to BiomX Ltd., a microbiome drug discovery company in Israel developing customized phage therapies, to develop and commercialize phage therapies based on such IP.

JSR news release, January 30, 2018